InvestorsHub Logo
Post# of 252465
Next 10
Followers 89
Posts 17445
Boards Moderated 0
Alias Born 09/06/2006

Re: iwfal post# 135445

Saturday, 01/21/2012 6:43:40 PM

Saturday, January 21, 2012 6:43:40 PM

Post# of 252465
Have you done any of the looking at historical rates of ORR in such a highly refractory population?

If you are not counting GNMBP status then I can find very similar trials, and that is were I guessed 5% from.

I have no clue at all about how G+ selection would affect this. I do see cites that it is associated with outcomes (G+ has worse outcomes), but no sites on ORR.

EDIT: The Eribulan P3 trial was close in patient pool, and the comparator arm ORR was 5%.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.